Abstract
In the last two decades, strong observational and experimental evidence has been presented for the role of iron excess in cancer development. The hereditary hemochromatosis gene HFE variants that increase body iron levels are associated with increased cancer risk. The first such association was reported by us in childhood acute lymphoblastic leukemia. With the identification of molecular mechanisms of potentiation of carcinogenesis by iron, epidemiologic associations have been gaining more weight. Experimental data also increase the credibility of suggestions that iron excess can both initiate (genotoxic effect) and promote (via its effect on immune function) cancer development. Both environmental and genetic factors may lead to iron excess but the effect is strongest in combination. Iron excess may contribute to cancer development in many different ways, most of which yet unappreciated and most relevant of those possible connections are discussed in this chapter. Since reduction in smoking, alcohol and red meat consumption eliminates excessive exposure to iron, eating fruits and vegetables does not expose the body to too much bioavailable iron and perhaps replaces other iron-rich food stuff and avoidance of excess iron levels reduces infections, iron is indirectly involved in the success of these preventive measures. Perhaps it is time to emphasize lower exposure to environmental iron directly as an important factor to reduce the cancer burden in the industrialized world.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Acton, R.T., Snively, B.M., Barton, J.C., McLaren, C.E., Adams, P.C., Rich, S.S., Eckfeldt, J.H., Press, R.D., Sholinsky, P., Leiendecker-Foster, C., McLaren, G.D., Speechley, M.R., Harris, E.L., Dawkins, F.W., Gordeuk, V.R., 2007. A genome-wide linkage scan for iron phenotype quantitative trait loci: the HEIRS Family Study. Clin Genet 71, 518–529.
Adams, P.C., 1994. Prevalence of abnormal iron studies in heterozygotes for hereditary hemochromatosis: an analysis of 255 heterozygotes. Am J Hematol 45, 146–149.
Ali, M.A., Akhmedkhanov, A., Zeleniuch-Jaquotte, A., Toniolo, P., Frenkel, K., Huang, X., 2003. Reliability of serum iron, ferritin, nitrite, and association with risk of renal cancer in women. Cancer Detect Prev 27, 116–121.
Ames, B.N., Gold, L.S., 1997. The causes and prevention of cancer: gaining perspective. Environ Health Perspect 105(Suppl 4), 865–873.
Ames, B.N., Wakimoto, P., 2002. Are vitamin and mineral deficiencies a major cancer risk? Nat Rev Cancer 2, 694–704.
Ammann, R.W., Muller, E., Bansky, J., Schuler, G., Hacki, W.H., 1980. High incidence of extrahepatic carcinomas in idiopathic hemochromatosis. Scand J Gastroenterol 15, 733–736.
Andrews, N.C., 2009. Genes determining blood cell traits. Nat Genet 41, 1161–1162.
Balder, H.F., Vogel, J., Jansen, M.C., Weijenberg, M.P., van den Brandt, P.A., Westenbrink, S., van der Meer, R., Goldbohm, R.A., 2006. Heme and chlorophyll intake and risk of colorectal cancer in the Netherlands cohort study. Cancer Epidemiol Biomarkers Prev 15, 717–725.
Barton, J.C., Harmon, L., Rivers, C., Acton, R.T., 1996. Hemochromatosis: association of severity of iron overload with genetic markers. Blood Cells Mol Dis 22, 195–204.
Barton, J.C., Lee, P.L., West, C., Bottomley, S.S., 2006. Iron overload and prolonged ingestion of iron supplements: clinical features and mutation analysis of hemochromatosis-associated genes in four cases. Am J Hematol 81, 760–767.
Barton, J.C., Shih, W.W., Sawada-Hirai, R., Acton, R.T., Harmon, L., Rivers, C., Rothenberg, B.E., 1997. Genetic and clinical description of hemochromatosis probands and heterozygotes: evidence that multiple genes linked to the major histocompatibility complex are responsible for hemochromatosis. Blood Cells Mol Dis 23, 135–145; discussion 145a-b.
Beckman, L.E., Van Landeghem, G.F., Sikstrom, C., Wahlin, A., Markevarn, B., Hallmans, G., Lenner, P., Athlin, L., Stenling, R., Beckman, L., 1999. Interaction between haemochromatosis and transferrin receptor genes in different neoplastic disorders. Carcinogenesis 20, 1231–1233.
Bell, H., Berg, J.P., Undlien, D.E., Distante, S., Raknerud, N., Heier, H.E., Try, K., Thomassen, Y., Haug, E., Raha-Chowdhury, R., Thorsby, E., 2000. The clinical expression of hemochromatosis in Oslo, Norway. Excessive oral iron intake may lead to secondary hemochromatosis even in HFE C282Y mutation negative subjects. Scand J Gastroenterol 35, 1301–1307.
Bensaid, M., Fruchon, S., Mazeres, C., Bahram, S., Roth, M.P., Coppin, H., 2004. Multigenic control of hepatic iron loading in a murine model of hemochromatosis. Gastroenterology 126, 1400–1408.
Benyamin, B., Ferreira, M.A., Willemsen, G., Gordon, S., Middelberg, R.P., McEvoy, B.P., Hottenga, J.J., Henders, A.K., Campbell, M.J., Wallace, L., Frazer, I.H., Heath, A.C., de Geus, E.J., Nyholt, D.R., Visscher, P.M., Penninx, B.W., Boomsma, D.I., Martin, N.G., Montgomery, G.W., Whitfield, J.B., 2009a. Common variants in TMPRSS6 are associated with iron status and erythrocyte volume. Nat Genet 41(11), 1173–1175.
Benyamin, B., McRae, A.F., Zhu, G., Gordon, S., Henders, A.K., Palotie, A., Peltonen, L., Martin, N.G., Montgomery, G.W., Whitfield, J.B., Visscher, P.M., 2009b. Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels. Am J Hum Genet 84, 60–65.
Beral, V., Bull, D., Doll, R., Peto, R., Reeves, G., 2004. Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83000 women with breast cancer from 16 countries. Lancet 363, 1007–1016.
Bergeron, R.J., 1986. Iron: a controlling nutrient in proliferative processes. Trends Biochem Sci 11, 133–136.
Blanck, H.M., Cogswell, M.E., Gillespie, C., Reyes, M., 2005. Iron supplement use and iron status among US adults: results from the third National Health and Nutrition Examination Survey. Am J Clin Nutr 82, 1024–1031.
Borgna-Pignatti, C., Castriota-Scanderbeg, A., 1991. Methods for evaluating iron stores and efficacy of chelation in transfusional hemosiderosis. Haematologica 76, 409–413.
Boult, J., Roberts, K., Brookes, M.J., Hughes, S., Bury, J.P., Cross, S.S., Anderson, G.J., Spychal, R., Iqbal, T., Tselepis, C., 2008. Overexpression of cellular iron import proteins is associated with malignant progression of esophageal adenocarcinoma. Clin Cancer Res 14, 379–387.
Bradbear, R.A., Bain, C., Siskind, V., Schofield, F.D., Webb, S., Axelsen, E.M., Halliday, J.W., Bassett, M.L., Powell, L.W., 1985. Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases. J Natl Cancer Inst 75, 81–84.
Bray, F., McCarron, P., Parkin, D.M., 2004. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 6, 229–239.
Bridle, K., Cheung, T.K., Murphy, T., Walters, M., Anderson, G., Crawford, D.G., Fletcher, L.M., 2006. Hepcidin is down-regulated in alcoholic liver injury: implications for the pathogenesis of alcoholic liver disease. Alcohol Clin Exp Res 30, 106–112.
Brissot, P., Bourel, M., Herry, D., Verger, J.P., Messner, M., Beaumont, C., Regnouard, F., Ferrand, B., Simon, M., 1981. Assessment of liver iron content in 271 patients: a reevaluation of direct and indirect methods. Gastroenterology 80, 557–565.
Brock, J.H., Mulero, V., 2000. Cellular and molecular aspects of iron and immune function. Proc Nutr Soc 59, 537–540.
Bulaj, Z.J., Griffen, L.M., Jorde, L.B., Edwards, C.Q., Kushner, J.P., 1996. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med 335, 1799–1805.
Butterworth, J.R., 2006. Another important function for an old friend! The role of iron in colorectal carcinogenesis. Gut 55, 1384–1386.
Cade, J.E., Moreton, J.A., O’Hara, B., Greenwood, D.C., Moor, J., Burley, V.J., Kukalizch, K., Bishop, D.T., Worwood, M., 2005. Diet and genetic factors associated with iron status in middle-aged women. Am J Clin Nutr 82, 813–820.
Cartwright, R.A., Gurney, K.A., Moorman, A.V., 2002. Sex ratios and the risks of haematological malignancies. Br J Haematol 118, 1071–1077.
Cazzola, M., Bergamaschi, G., Dezza, L., Arosio, P., 1990. Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: achievements and prospects. Blood 75, 1903–1919.
Chambers, J.C., Zhang, W., Li, Y., Sehmi, J., Wass, M.N., Zabaneh, D., Hoggart, C., Bayele, H., McCarthy, M.I., Peltonen, L., Freimer, N.B., Srai, S.K., Maxwell, P.H., Sternberg, M.J., Ruokonen, A., Abecasis, G., Jarvelin, M.R., Scott, J., Elliott, P., Kooner, J.S., 2009. Genome-wide association study identifies variants in TMPRSS6 associated with hemoglobin levels. Nat Genet 41, 1170–1172.
Chen, G., Fillebeen, C., Wang, J., Pantopoulos, K., 2007. Overexpression of iron regulatory protein 1 suppresses growth of tumor xenografts. Carcinogenesis 28, 785–791.
Chida, Y., Hamer, M., Wardle, J., Steptoe, A., 2008. Do stress-related psychosocial factors contribute to cancer incidence and survival? Nat Clin Pract Oncol 5, 466–475.
Chua, A.C., Herbison, C.E., Drake, S.F., Graham, R.M., Olynyk, J.K., Trinder, D., 2008. The role of Hfe in transferrin-bound iron uptake by hepatocytes. Hepatology 47, 1737–1744.
Cogswell, M.E., Parvanta, I., Ickes, L., Yip, R., Brittenham, G.M., 2003. Iron supplementation during pregnancy, anemia, and birth weight: a randomized controlled trial. Am J Clin Nutr 78, 773–781.
Colditz, G.A., Sellers, T.A., Trapido, E., 2006. Epidemiology – identifying the causes and preventability of cancer? Nat Rev Cancer 6, 75–83.
Conte, D., Narindrasorasak, S., Sarkar, B., 1996. In vivo and in vitro iron-replaced zinc finger generates free radicals and causes DNA damage. J Biol Chem 271, 5125–5130.
Cook, J.D., Watson, S.S., Simpson, K.M., Lipschitz, D.A., Skikne, B.S., 1984. The effect of high ascorbic acid supplementation on body iron stores. Blood 64, 721–726.
Coppin, H., Darnaud, V., Kautz, L., Meynard, D., Aubry, M., Mosser, J., Martinez, M., Roth, M.P., 2007. Gene expression profiling of Hfe-/- liver and duodenum in mouse strains with differing susceptibilities to iron loading: identification of transcriptional regulatory targets of Hfe and potential hemochromatosis modifiers. Genome Biol 8, R221.
Courselaud, B., Troadec, M.B., Fruchon, S., Ilyin, G., Borot, N., Leroyer, P., Coppin, H., Brissot, P., Roth, M.P., Loreal, O., 2004. Strain and gender modulate hepatic hepcidin 1 and 2 mRNA expression in mice. Blood Cells Mol Dis 32, 283–289.
Courville, P., Chaloupka, R., Cellier, M.F., 2006. Recent progress in structure-function analyses of Nramp proton-dependent metal-ion transporters. Biochem Cell Biol 84, 960–978.
Cruz, E., Vieira, J., Almeida, S., Lacerda, R., Gartner, A., Cardoso, C.S., Alves, H., Porto, G., 2006. A study of 82 extended HLA haplotypes in HFE-C282Y homozygous hemochromatosis subjects: relationship to the genetic control of CD8+ T-lymphocyte numbers and severity of iron overload. BMC Med Genet 7, 16.
Dai, J., Huang, C., Wu, J., Yang, C., Frenkel, K., Huang, X., 2004. Iron-induced interleukin-6 gene expression: possible mediation through the extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways. Toxicology 203, 199–209.
Danaei, G., Vander Hoorn, S., Lopez, A.D., Murray, C.J., Ezzati, M., 2005. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 366, 1784–1793.
Datz, C., Haas, T., Rinner, H., Sandhofer, F., Patsch, W., Paulweber, B., 1998. Heterozygosity for the C282Y mutation in the hemochromatosis gene is associated with increased serum iron, transferrin saturation, and hemoglobin in young women: a protective role against iron deficiency? Clin Chem 44, 2429–2432.
Davis, C.F., Dorak, M.T., 2010. An extensive analysis of the hereditary hemochromatosis gene HFE and neighboring histone genes: associations with childhood leukemia. Ann Hematol 89(4), 375–384.
De Freitas, J.M., Meneghini, R., 2001. Iron and its sensitive balance in the cell. Mutat Res 475, 153–159.
de Lorgeril, M., Salen, P., Martin, J.L., Monjaud, I., Boucher, P., Mamelle, N., 1998. Mediterranean dietary pattern in a randomized trial: prolonged survival and possible reduced cancer rate. Arch Intern Med 158, 1181–1187.
de Sousa, M., 1989. Immune cell functions in iron overload. Clin Exp Immunol 75, 1–6.
de Valk, B., Witlox, R.S., van der Schouw, Y.T., Marx, J.J., 2000. Biochemical expression of heterozygous hereditary hemochromatosis. Eur J Intern Med 11, 317–321.
de Vogel, J., Jonker-Termont, D.S., van Lieshout, E.M., Katan, M.B., van der Meer, R., 2005. Green vegetables, red meat and colon cancer: chlorophyll prevents the cytotoxic and hyperproliferative effects of haem in rat colon. Carcinogenesis 26, 387–393.
Deugnier, Y., Mosser, J., 2008. Modifying factors of the HFE hemochromatosis phenotype. Expert Rev Gastroenterol Hepatol 2, 531–540.
Deugnier, Y., Turlin, B., 2001. Iron and hepatocellular carcinoma. J Gastroenterol Hepatol 16, 491–494.
Distante, S., Berg, J.P., Lande, K., Haug, E., Bell, H., 1999. High prevalence of the hemochromatosis-associated Cys282Tyr HFE gene mutation in a healthy Norwegian population in the city of Oslo, and its phenotypic expression. Scand J Gastroenterol 34, 529–534.
Donovan, A., Lima, C.A., Pinkus, J.L., Pinkus, G.S., Zon, L.I., Robine, S., Andrews, N.C., 2005. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab 1, 191–200.
Dorak, M.T., 2006. HFE H63D variant and leukemia susceptibility. Leuk Lymphoma 47, 2269–2270.
Dorak, M.T., Burnett, A.K., Worwood, M., 2005. HFE gene mutations in susceptibility to childhood leukemia: HuGE review. Genet Med 7, 159–168.
Dorak, M.T., Mackay, R.K., Relton, C.L., Worwood, M., Parker, L., Hall, A.G., 2009. Hereditary hemochromatosis gene (HFE) variants are associated with birth weight and childhood leukemia risk. Pediatr Blood Cancer 53, 1242–1248.
Dorak, M.T., Sproul, A.M., Gibson, B.E., Burnett, A.K., Worwood, M., 1999. The C282Y mutation of HFE is another male-specific risk factor for childhood ALL. Blood 94, 3957–3958.
Dunn, G.P., Old, L.J., Schreiber, R.D., 2004. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21, 137–148.
Dunn, L.L., Rahmanto, Y.S., Richardson, D.R., 2007. Iron uptake and metabolism in the new millennium. Trends Cell Biol 17, 93–100.
Dupic, F., Fruchon, S., Bensaid, M., Borot, N., Radosavljevic, M., Loreal, O., Brissot, P., Gilfillan, S., Bahram, S., Coppin, H., Roth, M.P., 2002. Inactivation of the hemochromatosis gene differentially regulates duodenal expression of iron-related mRNAs between mouse strains. Gastroenterology 122, 745–751.
Eaton, J.W., Qian, M., 2002. Molecular bases of cellular iron toxicity. Free Radic Biol Med 32, 833–840.
Edgren, G., Reilly, M., Hjalgrim, H., Tran, T.N., Rostgaard, K., Adami, J., Titlestad, K., Shanwell, A., Melbye, M., Nyren, O., 2008. Donation frequency, iron loss, and risk of cancer among blood donors. J Natl Cancer Inst 100, 572–579.
Elliott, R.L., Elliott, M.C., Wang, F., Head, J.F., 1993. Breast carcinoma and the role of iron metabolism. A cytochemical, tissue culture, and ultrastructural study. Ann N Y Acad Sci 698, 159–166.
Elmberg, M., Hultcrantz, R., Ekbom, A., Brandt, L., Olsson, S., Olsson, R., Lindgren, S., Loof, L., Stal, P., Wallerstedt, S., Almer, S., Sandberg-Gertzen, H., Askling, J., 2003. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 125, 1733–1741.
Ershler, W.B., 1993. The influence of an aging immune system on cancer incidence and progression. J Gerontol 48, B3–B7.
Feder, J.N., Gnirke, A., Thomas, W., Tsuchihashi, Z., Ruddy, D.A., Basava, A., Dormishian, F., Domingo, R., Jr., Ellis, M.C., Fullan, A., Hinton, L.M., Jones, N.L., Kimmel, B.E., Kronmal, G.S., Lauer, P., Lee, V.K., Loeb, D.B., Mapa, F.A., McClelland, E., Meyer, N.C., Mintier, G.A., Moeller, N., Moore, T., Morikang, E., Prass, C.E., Quintana, L., Starnes, S.M., Schatzman, R.C., Brunke, K.J., Drayna, D.T., Risch, N.J., Bacon, B.R., Wolff, R.K., 1996. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 13, 399–408.
Feng, Z., Hu, W., Teresky, A.K., Hernando, E., Cordon-Cardo, C., Levine, A.J., 2007. Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations. Proc Natl Acad Sci U S A 104, 16633–16638.
Fleming, D.J., Jacques, P.F., Dallal, G.E., Tucker, K.L., Wilson, P.W., Wood, R.J., 1998. Dietary determinants of iron stores in a free-living elderly population: the Framingham Heart Study. Am J Clin Nutr 67, 722–733.
Fleming, D.J., Jacques, P.F., Massaro, J.M., D’Agostino, R.B., Sr., Wilson, P.W., Wood, R.J., 2001a. Aspirin intake and the use of serum ferritin as a measure of iron status. Am J Clin Nutr 74, 219–226.
Fleming, D.J., Jacques, P.F., Tucker, K.L., Massaro, J.M., D’Agostino, R.B., Sr., Wilson, P.W., Wood, R.J., 2001b. Iron status of the free-living, elderly Framingham Heart Study cohort: an iron-replete population with a high prevalence of elevated iron stores. Am J Clin Nutr 73, 638–646.
Fleming, D.J., Tucker, K.L., Jacques, P.F., Dallal, G.E., Wilson, P.W., Wood, R.J., 2002. Dietary factors associated with the risk of high iron stores in the elderly Framingham Heart Study cohort. Am J Clin Nutr 76, 1375–1384.
Fleming, R.E., Holden, C.C., Tomatsu, S., Waheed, A., Brunt, E.M., Britton, R.S., Bacon, B.R., Roopenian, D.C., Sly, W.S., 2001c. Mouse strain differences determine severity of iron accumulation in Hfe knockout model of hereditary hemochromatosis. Proc Natl Acad Sci U S A 98, 2707–2711.
Ganesh, S.K., Zakai, N.A., van Rooij, F.J., Soranzo, N., Smith, A.V., Nalls, M.A., Chen, M.H., Kottgen, A., Glazer, N.L., Dehghan, A., Kuhnel, B., Aspelund, T., Yang, Q., Tanaka, T., Jaffe, A., Bis, J.C., Verwoert, G.C., Teumer, A., Fox, C.S., Guralnik, J.M., Ehret, G.B., Rice, K., Felix, J.F., Rendon, A., Eiriksdottir, G., Levy, D., Patel, K.V., Boerwinkle, E., Rotter, J.I., Hofman, A., Sambrook, J.G., Hernandez, D.G., Zheng, G., Bandinelli, S., Singleton, A.B., Coresh, J., Lumley, T., Uitterlinden, A.G., Vangils, J.M., Launer, L.J., Cupples, L.A., Oostra, B.A., Zwaginga, J.J., Ouwehand, W.H., Thein, S.L., Meisinger, C., Deloukas, P., Nauck, M., Spector, T.D., Gieger, C., Gudnason, V., van Duijn, C.M., Psaty, B.M., Ferrucci, L., Chakravarti, A., Greinacher, A., O’Donnell, C.J., Witteman, J.C., Furth, S., Cushman, M., Harris, T.B., Lin, J.P., 2009. Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. Nat Genet 41, 1191–1198.
Geier, D., Hebert, B., Potti, A., 2002. Risk of primary non-hepatocellular malignancies in hereditary hemochromatosis. Anticancer Res 22, 3797–3799.
Gochee, P.A., Powell, L.W., Cullen, D.J., Du Sart, D., Rossi, E., Olynyk, J.K., 2002. A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology 122, 646–651.
Good, M.F., Powell, L.W., Halliday, J.W., 1988. Iron status and cellular immune competence. Blood Rev 2, 43–49.
Gordeuk, V., Mukiibi, J., Hasstedt, S.J., Samowitz, W., Edwards, C.Q., West, G., Ndambire, S., Emmanual, J., Nkanza, N., Chapanduka, Z., et al., , 1992. Iron overload in Africa. Interaction between a gene and dietary iron content. N Engl J Med 326, 95–100.
Green, P., Eviatar, J.M., Sirota, P., Avidor, I., 1989. Secondary hemochromatosis due to prolonged iron ingestion. Isr J Med Sci 25, 199–201.
Greenwald, P., Anderson, D., Nelson, S.A., Taylor, P.R., 2007. Clinical trials of vitamin and mineral supplements for cancer prevention. Am J Clin Nutr 85, 314S–317S.
Greenwald, P., Dunn, B.K., 2009. Landmarks in the history of cancer epidemiology. Cancer Res 69, 2151–2162.
Greenwood, D.C., Cade, J.E., Moreton, J.A., O’Hara, B., Burley, V.J., Randerson-Moor, J.A., Kukalizch, K., Thompson, D., Worwood, M., Bishop, D.T., 2005. HFE genotype modifies the influence of heme iron intake on iron status. Epidemiology 16, 802–805.
Hallberg, L., Hulten, L., Gramatkovski, E., 1997. Iron absorption from the whole diet in men: how effective is the regulation of iron absorption? Am J Clin Nutr 66, 347–356.
Hallberg, L., Hulthen, L., 2003. High serum ferritin is not identical to high iron stores. Am J Clin Nutr 78, 1225–1226.
Hann, H.W., Stahlhut, M.W., Blumberg, B.S., 1988. Iron nutrition and tumor growth: decreased tumor growth in iron-deficient mice. Cancer Res 48, 4168–4170.
Hann, H.W., Stahlhut, M.W., Menduke, H., 1991. Iron enhances tumor growth. Observation on spontaneous mammary tumors in mice. Cancer 68, 2407–2410.
Harrison-Findik, D.D., 2007. Role of alcohol in the regulation of iron metabolism. World J Gastroenterol 13, 4925–4930.
Harrison-Findik, D.D., Klein, E., Crist, C., Evans, J., Timchenko, N., Gollan, J., 2007. Iron-mediated regulation of liver hepcidin expression in rats and mice is abolished by alcohol. Hepatology 46, 1979–1985.
Harrison-Findik, D.D., Schafer, D., Klein, E., Timchenko, N.A., Kulaksiz, H., Clemens, D., Fein, E., Andriopoulos, B., Pantopoulos, K., Gollan, J., 2006. Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression. J Biol Chem 281, 22974–22982.
Heath, A.L., Roe, M.A., Oyston, S.L., Gray, A.R., Williams, S.M., Fairweather-Tait, S.J., 2008. Blood loss is a stronger predictor of iron status in men than C282Y heterozygosity or diet. J Am Coll Nutr 27, 158–167.
Hemminki, K., Lorenzo Bermejo, J., Forsti, A., 2006. The balance between heritable and environmental etiology of human disease. Nat Rev Genet 7, 958–965.
Herbert, V., Jayatilleke, E., Shaw, S., Rosman, A.S., Giardina, P., Grady, R.W., Bowman, B., Gunter, E.W., 1997. Serum ferritin iron, a new test, measures human body iron stores unconfounded by inflammation. Stem Cells 15, 291–296.
Herbert, V., Shaw, S., Jayatilleke, E., Stopler-Kasdan, T., 1994. Most free-radical injury is iron-related: it is promoted by iron, hemin, holoferritin and vitamin C, and inhibited by desferoxamine and apoferritin. Stem Cells 12, 289–303.
Hong, C.C., Ambrosone, C.B., Ahn, J., Choi, J.Y., McCullough, M.L., Stevens, V.L., Rodriguez, C., Thun, M.J., Calle, E.E., 2007. Genetic variability in iron-related oxidative stress pathways (Nrf2, NQ01, NOS3, and HO-1), iron intake, and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 16, 1784–1794.
Hsing, A.W., McLaughlin, J.K., Olsen, J.H., Mellemkjar, L., Wacholder, S., Fraumeni, J.F., Jr., 1995. Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark. Int J Cancer 60, 160–162.
Huang, X., 2003. Iron overload and its association with cancer risk in humans: evidence for iron as a carcinogenic metal. Mutat Res 533, 153–171.
Huang, X., 2008. Does iron have a role in breast cancer? Lancet Oncol 9, 803–807.
Hunt, J.R., Zeng, H., 2004. Iron absorption by heterozygous carriers of the HFE C282Y mutation associated with hemochromatosis. Am J Clin Nutr 80, 924–931.
Hussain, S.P., Hofseth, L.J., Harris, C.C., 2003. Radical causes of cancer. Nat Rev Cancer 3, 276–285.
Jackson, H.A., Carter, K., Darke, C., Guttridge, M.G., Ravine, D., Hutton, R.D., Napier, J.A., Worwood, M., 2001. HFE mutations, iron deficiency and overload in 10,500 blood donors. Br J Haematol 114, 474–484.
Jacolot, S., Le Gac, G., Scotet, V., Quere, I., Mura, C., Ferec, C., 2004. HAMP as a modifier gene that increases the phenotypic expression of the HFE pC282Y homozygous genotype. Blood 103, 2835–2840.
Jalihal, S.S., Barlow, A.M., 1984. Haemochromatosis following prolonged oral iron ingestion. J R Soc Med 77, 690–692.
Jezerniczky, J., Nagy, Z., Dvoracsek, E., Nagy, B., Ilyes, I., Csorba, S., 1976. Trace elements in the serum of mothers and their children. Acta Paediatr Acad Sci Hung 17, 193–197.
Kabat, G.C., Miller, A.B., Jain, M., Rohan, T.E., 2007. Dietary iron and heme iron intake and risk of breast cancer: a prospective cohort study. Cancer Epidemiol Biomarkers Prev 16, 1306–1308.
Kabat, G.C., Rohan, T.E., 2007. Does excess iron play a role in breast carcinogenesis? An unresolved hypothesis. Cancer Causes Control 18, 1047–1053.
Kakhlon, O., Cabantchik, Z.I., 2002. The labile iron pool: characterization, measurement, and participation in cellular processes. Free Radic Biol Med 33, 1037–1046.
Kaltwasser, J.P., Gottschalk, R., Schalk, K.P., Hartl, W., 1990. Non-invasive quantitation of liver iron-overload by magnetic resonance imaging. Br J Haematol 74, 360–363.
Kaltwasser, J.P., Werner, E., Schalk, K., Hansen, C., Gottschalk, R., Seidl, C., 1998. Clinical trial on the effect of regular tea drinking on iron accumulation in genetic haemochromatosis. Gut 43, 699–704.
Kaomongkolgit, R., Cheepsunthorn, P., Pavasant, P., Sanchavanakit, N., 2008. Iron increases MMP-9 expression through activation of AP-1 via ERK/Akt pathway in human head and neck squamous carcinoma cells. Oral Oncol 44, 587–594.
Kato, I., Dnistrian, A.M., Schwartz, M., Toniolo, P., Koenig, K., Shore, R.E., Zeleniuch-Jacquotte, A., Akhmedkhanov, A., Riboli, E., 1999. Iron intake, body iron stores and colorectal cancer risk in women: a nested case-control study. Int J Cancer 80, 693–698.
Kato, I., Dnistrian, A.M., Schwartz, M., Toniolo, P., Koenig, K., Shore, R.E., Zeleniuch-Jacquotte, A., Akhmedkhanov, A., Riboli, E., 2000. Risk of iron overload among middle-aged women. Int J Vitam Nutr Res 70, 119–125.
Kell, D.B., 2009. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics 2, 2.
Kerenyi, M.A., Grebien, F., Gehart, H., Schifrer, M., Artaker, M., Kovacic, B., Beug, H., Moriggl, R., Mullner, E.W., 2008. Stat5 regulates cellular iron uptake of erythroid cells via IRP-2 and TfR-1. Blood 112, 3878–3888.
Kew, M.C., 2008. Hepatic iron overload and hepatocellular carcinoma. Cancer Lett 286(1), 38–43.
Kew, M.C., Asare, G.A., 2007. Dietary iron overload in the African and hepatocellular carcinoma. Liver Int 27, 735–741.
Kiecolt-Glaser, J.K., Robles, T.F., Heffner, K.L., Loving, T.J., Glaser, R., 2002. Psycho-oncology and cancer: psychoneuroimmunology and cancer. Ann Oncol 13(Suppl 4), 165–169.
Kinlen, L., 2004. Infections and immune factors in cancer: the role of epidemiology. Oncogene 23, 6341–6348.
Knekt, P., Reunanen, A., Takkunen, H., Aromaa, A., Heliovaara, M., Hakulinen, T., 1994. Body iron stores and risk of cancer. Int J Cancer 56, 379–382.
Kohgo, Y., Ikuta, K., Ohtake, T., Torimoto, Y., Kato, J., 2007. Iron overload and cofactors with special reference to alcohol, hepatitis C virus infection and steatosis/insulin resistance. World J Gastroenterol 13, 4699–4706.
Kovacevic, Z., Richardson, D.R., 2006. The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis 27, 2355–2366.
Kowdley, K.V., 2004. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 127, S79–S86.
Kruszewski, M., 2003. Labile iron pool: the main determinant of cellular response to oxidative stress. Mutat Res 531, 81–92.
Kwok, J.C., Richardson, D.R., 2002. The iron metabolism of neoplastic cells: alterations that facilitate proliferation? Crit Rev Oncol Hematol 42, 65–78.
Lakhal, S., Talbot, N.P., Crosby, A., Stoepker, C., Townsend, A.R., Robbins, P.A., Pugh, C.W., Ratcliffe, P.J., Mole, D.R., 2009. Regulation of growth differentiation factor 15 expression by intracellular iron. Blood 113, 1555–1563.
Larramendy, M., Mello-Filho, A.C., Martins, E.A., Meneghini, R., 1987. Iron-mediated induction of sister-chromatid exchanges by hydrogen peroxide and superoxide anion. Mutat Res 178, 57–63.
Lauffer, R.B., 1991. Exercise as prevention: do the health benefits derive in part from lower iron levels? Med Hypotheses 35, 103–107.
Lawson, K.A., Wright, M.E., Subar, A., Mouw, T., Hollenbeck, A., Schatzkin, A., Leitzmann, M.F., 2007. Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health Study. J Natl Cancer Inst 99, 754–764.
Le Lan, C., Loreal, O., Cohen, T., Ropert, M., Glickstein, H., Laine, F., Pouchard, M., Deugnier, Y., Le Treut, A., Breuer, W., Cabantchik, Z.I., Brissot, P., 2005. Redox active plasma iron in C282Y/C282Y hemochromatosis. Blood 105, 4527–4531.
Le Marchand, L., 2005. The predominance of the environment over genes in cancer causation: implications for genetic epidemiology. Cancer Epidemiol Biomarkers Prev 14, 1037–1039.
Le, N.T., Richardson, D.R., 2002. The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta 1603, 31–46.
Lecube, A., Hernandez, C., Pelegri, D., Simo, R., 2008. Factors accounting for high ferritin levels in obesity. Int J Obes (Lond) 32, 1665–1669.
Lee, D.H., Anderson, K.E., Folsom, A.R., Jacobs, D.R., Jr., 2005. Heme iron, zinc and upper digestive tract cancer: the Iowa Women’s Health Study. Int J Cancer 117, 643–647.
Lee, D.H., Anderson, K.E., Harnack, L.J., Folsom, A.R., Jacobs, D.R., Jr., 2004. Heme iron, zinc, alcohol consumption, and colon cancer: Iowa Women’s Health Study. J Natl Cancer Inst 96, 403–407.
Leggett, B.A., Brown, N.N., Bryant, S.J., Duplock, L., Powell, L.W., Halliday, J.W., 1990. Factors affecting the concentrations of ferritin in serum in a healthy Australian population. Clin Chem 36, 1350–1355.
Lehmann, U., Wingen, L.U., Brakensiek, K., Wedemeyer, H., Becker, T., Heim, A., Metzig, K., Hasemeier, B., Kreipe, H., Flemming, P., 2007. Epigenetic defects of hepatocellular carcinoma are already found in non-neoplastic liver cells from patients with hereditary haemochromatosis. Hum Mol Genet 16, 1335–1342.
Lichtenstein, P., Holm, N.V., Verkasalo, P.K., Iliadou, A., Kaprio, J., Koskenvuo, M., Pukkala, E., Skytthe, A., Hemminki, K., 2000. Environmental and heritable factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343, 78–85.
Liehr, J.G., Jones, J.S., 2001. Role of iron in estrogen-induced cancer. Curr Med Chem 8, 839–849.
Lipinski, P., Drapier, J.C., Oliveira, L., Retmanska, H., Sochanowicz, B., Kruszewski, M., 2000. Intracellular iron status as a hallmark of mammalian cell susceptibility to oxidative stress: a study of L5178Y mouse lymphoma cell lines differentially sensitive to H(2)O(2). Blood 95, 2960–2966.
Liu, J.M., Hankinson, S.E., Stampfer, M.J., Rifai, N., Willett, W.C., Ma, J., 2003. Body iron stores and their determinants in healthy postmenopausal US women. Am J Clin Nutr 78, 1160–1167.
Madigan, M.P., Ziegler, R.G., Benichou, J., Byrne, C., Hoover, R.N., 1995. Proportion of breast cancer cases in the United States explained by well-established risk factors. J Natl Cancer Inst 87, 1681–1685.
Mainous, A.G., 3rd, Gill, J.M., Carek, P.J., 2004. Elevated serum transferrin saturation and mortality. Ann Fam Med 2, 133–138.
Mainous, A.G., 3rd, Gill, J.M., Everett, C.J., 2005a. Transferrin saturation, dietary iron intake, and risk of cancer. Ann Fam Med 3, 131–137.
Mainous, A.G., 3rd, Wells, B.J., Koopman, R.J., Everett, C.J., Gill, J.M., 2005b. Iron, lipids, and risk of cancer in the Framingham Offspring cohort. Am J Epidemiol 161, 1115–1122.
Mallory, M.A., Kowdley, K.V., 2001. Hereditary hemochromatosis and cancer risk: more fuel to the fire? more fuel to the fire? Gastroenterology 121, 1253–1254.
Martinez di Montemuros, F., Tavazzi, D., Salsano, E., Piepoli, T., Pollo, B., Fiorelli, G., Finocchiaro, G., 2001. High frequency of the H63D mutation of the hemochromatosis gene (HFE) in malignant gliomas. Neurology 57, 1342.
Martins, E.A., Robalinho, R.L., Meneghini, R., 1995. Oxidative stress induces activation of a cytosolic protein responsible for control of iron uptake. Arch Biochem Biophys 316, 128–134.
Mascitelli, L., Pezzetta, F., Sullivan, J.L., 2009. Aspirin-associated iron loss as an anticancer mechanism. Med Hypotheses 74(1), 78–80.
Matsha, T., Brink, L., van Rensburg, S., Hon, D., Lombard, C., Erasmus, R., 2006. Traditional home-brewed beer consumption and iron status in patients with esophageal cancer and healthy control subjects from Transkei, South Africa. Nutr Cancer 56, 67–73.
McCord, J.M., 2004. Iron, free radicals, and oxidative injury. J Nutr 134, 3171S–3172S.
McDermid, J.M., van der Loeff, M.F., Jaye, A., Hennig, B.J., Bates, C., Todd, J., Sirugo, G., Hill, A.V., Whittle, H.C., Prentice, A.M., 2009. Mortality in HIV infection is independently predicted by host iron status and SLC11A1 and HP genotypes, with new evidence of a gene-nutrient interaction. Am J Clin Nutr 90, 225–233.
McGregor, J., McKie, A.T., Simpson, R.J., 2004. Of mice and men: genetic determinants of iron status. Proc Nutr Soc 63, 11–20.
Mello Filho, A.C., Hoffmann, M.E., Meneghini, R., 1984. Cell killing and DNA damage by hydrogen peroxide are mediated by intracellular iron. Biochem J 218, 273–275.
Meneghini, R., 1997. Iron homeostasis, oxidative stress, and DNA damage. Free Radic Biol Med 23, 783–792.
Merk, K., Mattsson, B., Mattsson, A., Holm, G., Gullbring, B., Bjorkholm, M., 1990. The incidence of cancer among blood donors. Int J Epidemiol 19, 505–509.
Merryweather-Clarke, A.T., Pointon, J.J., Jouanolle, A.M., Rochette, J., Robson, K.J., 2000. Geography of HFE C282Y and H63D mutations. Genet Test 4, 183–198.
Meynard, D., Kautz, L., Darnaud, V., Canonne-Hergaux, F., Coppin, H., Roth, M.P., 2009. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet 41, 478–481.
Milet, J., Dehais, V., Bourgain, C., Jouanolle, A.M., Mosser, A., Perrin, M., Morcet, J., Brissot, P., David, V., Deugnier, Y., Mosser, J., 2007. Common variants in the BMP2, BMP4, and HJV genes of the hepcidin regulation pathway modulate HFE hemochromatosis penetrance. Am J Hum Genet 81, 799–807.
Milman, N., 1996. Serum ferritin in Danes: studies of iron status from infancy to old age, during blood donation and pregnancy. Int J Hematol 63, 103–135.
Milman, N., Byg, K.E., Ovesen, L., Kirchhoff, M., Jurgensen, K.S., 2003. Iron status in Danish women, 1984–1994: a cohort comparison of changes in iron stores and the prevalence of iron deficiency and iron overload. Eur J Haematol 71, 51–61.
Milman, N., Kirchhoff, M., Jorgensen, T., 1992. Iron status markers, serum ferritin and hemoglobin in 1359 Danish women in relation to menstruation, hormonal contraception, parity, and postmenopausal hormone treatment. Ann Hematol 65, 96–102.
Milward, E.A., Baines, S.K., Knuiman, M.W., Bartholomew, H.C., Divitini, M.L., Ravine, D.G., Bruce, D.G., Olynyk, J.K., 2008. Noncitrus fruits as novel dietary environmental modifiers of iron stores in people with or without HFE gene mutations. Mayo Clin Proc 83, 543–549.
Miraglia Del Giudice, E., Santoro, N., Amato, A., Brienza, C., Calabro, P., Wiegerinck, E.T., Cirillo, G., Tartaglione, N., Grandone, A., Swinkels, D.W., Perrone, L., 2009. Hepcidin in Obese Children as a Potential Mediator of the Association between Obesity and Iron Deficiency. J Clin Endocrinol Metab 94(12), 5102–5107.
Mura, C., Le Gac, G., Raguenes, O., Mercier, A.Y., Le Guen, A., Ferec, C., 2000. Relation between HFE mutations and mild iron-overload expression. Mol Genet Metab 69, 295–301.
Mura, C., Le Gac, G., Scotet, V., Raguenes, O., Mercier, A.Y., Ferec, C., 2001. Variation of iron loading expression in C282Y homozygous haemochromatosis probands and sib pairs. J Med Genet 38, 632–636.
Mussalo-Rauhamaa, H., Leppanen, A., Salmela, S.S., Pyysalo, H., 1986. Cigarettes as a source of some trace and heavy metals and pesticides in man. Arch Environ Health 41, 49–55.
Nakano, M., Kawanishi, Y., Kamohara, S., Uchida, Y., Shiota, M., Inatomi, Y., Komori, T., Miyazawa, K., Gondo, K., Yamasawa, I., 2003. Oxidative DNA damage (8-hydroxydeoxyguanosine) and body iron status: a study on 2507 healthy people. Free Radic Biol Med 35, 826–832.
Nearman, Z.P., Szpurka, H., Serio, B., Warshawksy, I., Theil, K., Lichtin, A., Sekeres, M.A., Maciejewski, J.P., 2007. Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts. Am J Hematol 82, 1076–1079.
Nelson, R.L., 2001. Iron and colorectal cancer risk: human studies. Nutr Rev 59, 140–148.
Neuhouser, M.L., Wassertheil-Smoller, S., Thomson, C., Aragaki, A., Anderson, G.L., Manson, J.E., Patterson, R.E., Rohan, T.E., van Horn, L., Shikany, J.M., Thomas, A., LaCroix, A., Prentice, R.L., 2009. Multivitamin use and risk of cancer and cardiovascular disease in the Women’s Health Initiative cohorts. Arch Intern Med 169, 294–304.
O’Donnell, K.A., Yu, D., Zeller, K.I., Kim, J.W., Racke, F., Thomas-Tikhonenko, A., Dang, C.V., 2006. Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis. Mol Cell Biol 26, 2373–2386.
Olsson, K.S., Ritter, B., Hansson, N., 2007. The HLA-A1-B8 haplotype hitchhiking with the hemochromatosis mutation: does it affect the phenotype? Eur J Haematol 79, 429–434.
Olsson, K.S., Vaisanen, M., Konar, J., Bruce, A., 1997. The effect of withdrawal of food iron fortification in Sweden as studied with phlebotomy in subjects with genetic hemochromatosis. Eur J Clin Nutr 51, 782–786.
Olynyk, J.K., Cullen, D.J., Aquilia, S., Rossi, E., Summerville, L., Powell, L.W., 1999. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 341, 718–724.
Osler, M., Milman, N., Heitmann, B.L., 1999. Consequences of removing iron fortification of flour on iron status among Danish adults: some longitudinal observations between 1987 and 1994. Prev Med 29, 32–36.
Palma, S., Perez-Iglesias, R., Prieto, D., Pardo, R., Llorca, J., Delgado-Rodriguez, M., 2008. Iron but not folic acid supplementation reduces the risk of low birthweight in pregnant women without anaemia: a case-control study. J Epidemiol Community Health 62, 120–124.
Papanikolaou, G., Pantopoulos, K., 2005. Iron metabolism and toxicity. Toxicol Appl Pharmacol 202, 199–211.
Pedersen, P., Milman, N., 2009a. Extrinsic factors modifying expressivity of the HFE variant C282Y, H63D, S65C phenotypes in 1,294 Danish men. Ann Hematol 88(10), 957–965.
Pedersen, P., Milman, N., 2009b. Genetic screening for HFE hemochromatosis in 6,020 Danish men: penetrance of C282Y, H63D, and S65C variants. Ann Hematol 88(8), 775–784.
Pietrangelo, A., 2004. Hereditary hemochromatosis–a new look at an old disease. N Engl J Med 350, 2383–2397.
Pinto, J.P., Ramos, P., de Almeida, S.F., Oliveira, S., Breda, L., Michalak, M., Porto, G., Rivella, S., de Sousa, M., 2008. Protective role of calreticulin in HFE hemochromatosis. Free Radic Biol Med 44, 99–108.
Piperno, A., Sampietro, M., Pietrangelo, A., Arosio, C., Lupica, L., Montosi, G., Vergani, A., Fraquelli, M., Girelli, D., Pasquero, P., Roetto, A., Gasparini, P., Fargion, S., Conte, D., Camaschella, C., 1998. Heterogeneity of hemochromatosis in Italy. Gastroenterology 114, 996–1002.
Porto, G., De Sousa, M., 2007. Iron overload and immunity. World J Gastroenterol 13, 4707–4715.
Preziosi, P., Prual, A., Galan, P., Daouda, H., Boureima, H., Hercberg, S., 1997. Effect of iron supplementation on the iron status of pregnant women: consequences for newborns. Am J Clin Nutr 66, 1178–1182.
Raddatz, D., Legler, T., Lynen, R., Addicks, N., Ramadori, G., 2003. HFE genotype and parameters of iron metabolism in German first-time blood donors – evidence for an increased transferrin saturation in C282Y heterozygotes. Z Gastroenterol 41, 1069–1076.
Rochette, J., Pointon, J.J., Fisher, C.A., Perera, G., Arambepola, M., Arichchi, D.S., De Silva, S., Vandwalle, J.L., Monti, J.P., Old, J.M., Merryweather-Clarke, A.T., Weatherall, D.J., Robson, K.J., 1999. Multicentric origin of hemochromatosis gene (HFE) mutations. Am J Hum Genet 64, 1056–1062.
Roe, M.A., Heath, A.L., Oyston, S.L., Macrow, C., Hoogewerff, J.A., Foxall, R., Dainty, J.R., Majsak-Newman, G., Willis, G., Fairweather-Tait, S.J., 2005. Iron absorption in male C282Y heterozygotes. Am J Clin Nutr 81, 814–821.
Rossi, E., Bulsara, M.K., Olynyk, J.K., Cullen, D.J., Summerville, L., Powell, L.W., 2001. Effect of hemochromatosis genotype and lifestyle factors on iron and red cell indices in a community population. Clin Chem 47, 202–208.
Samarasena, J., Winsor, W., Lush, R., Duggan, P., Xie, Y., Borgaonkar, M., 2006. Individuals homozygous for the H63D mutation have significantly elevated iron indexes. Dig Dis Sci 51, 803–807.
Sanchez, M., Galy, B., Dandekar, T., Bengert, P., Vainshtein, Y., Stolte, J., Muckenthaler, M.U., Hentze, M.W., 2006. Iron regulation and the cell cycle: identification of an iron-responsive element in the 3’-untranslated region of human cell division cycle 14A mRNA by a refined microarray-based screening strategy. J Biol Chem 281, 22865–22874.
Schwartz, R.S., 2001. Immunodeficiency, immunosuppression, and susceptibility to neoplasms. J Natl Cancer Inst Monogr, 5–9.
Selby, J.V., Friedman, G.D., 1988. Epidemiologic evidence of an Association between body iron stores and risk of cancer. Int J Cancer 41, 677–682.
Shaheen, N.J., Silverman, L.M., Keku, T., Lawrence, L.B., Rohlfs, E.M., Martin, C.F., Galanko, J., Sandler, R.S., 2003. Association between hemochromatosis (HFE) gene mutation carrier status and the risk of colon cancer. J Natl Cancer Inst 95, 154–159.
Shi, Z., Johnstone, D., Talseth-Palmer, B.A., Evans, T.J., Spigelman, A.D., Groombridge, C., Milward, E.A., Olynyk, J.K., Suchy, J., Kurzawski, G., Lubinski, J., Scott, R.J., 2009. Haemochromatosis HFE gene polymorphisms as potential modifiers of hereditary nonpolyposis colorectal cancer risk and onset age. Int J Cancer 125, 78–83.
Simonart, T., 2006. Role of environmental factors in the pathogenesis of classic and African-endemic Kaposi sarcoma. Cancer Lett 244, 1–7.
Simonart, T., De Dobbeleer, G., Stallenberg, B., 2003. Classic Kaposi’s sarcoma of the palm in a metallurgist: role of iron filings in its development? Br J Dermatol 148, 1061–1063.
Simonart, T., Degraef, C., Stordeur, P., Noel, J.C., Mosselmans, R., Van Vooren, J.P., Parent, D., Boelaert, J.R., Heenen, M., Galand, P., 2001. Iron induces Bcl-2 expression in human dermal microvascular endothelial cells. Free Radic Res 34, 221–235.
Simonart, T., Noel, J.C., Andrei, G., Parent, D., Van Vooren, J.P., Hermans, P., Lunardi-Yskandar, Y., Lambert, C., Dieye, T., Farber, C.M., Liesnard, C., Snoeck, R., Heenen, M., Boelaert, J.R., 1998. Iron as a potential co-factor in the pathogenesis of Kaposi’s sarcoma? Int J Cancer 78, 720–726.
Sinha, R., Cross, A.J., Graubard, B.I., Leitzmann, M.F., Schatzkin, A., 2009. Meat intake and mortality: a prospective study of over half a million people. Arch Intern Med 169, 562–571.
Sofi, F., Cesari, F., Abbate, R., Gensini, G.F., Casini, A., 2008. Adherence to Mediterranean diet and health status: meta-analysis. BMJ 337, a1344.
Soranzo, N., Spector, T.D., Mangino, M., Kuhnel, B., Rendon, A., Teumer, A., Willenborg, C., Wright, B., Chen, L., Li, M., Salo, P., Voight, B.F., Burns, P., Laskowski, R.A., Xue, Y., Menzel, S., Altshuler, D., Bradley, J.R., Bumpstead, S., Burnett, M.S., Devaney, J., Doring, A., Elosua, R., Epstein, S.E., Erber, W., Falchi, M., Garner, S.F., Ghori, M.J., Goodall, A.H., Gwilliam, R., Hakonarson, H.H., Hall, A.S., Hammond, N., Hengstenberg, C., Illig, T., Konig, I.R., Knouff, C.W., McPherson, R., Melander, O., Mooser, V., Nauck, M., Nieminen, M.S., O’Donnell, C.J., Peltonen, L., Potter, S.C., Prokisch, H., Rader, D.J., Rice, C.M., Roberts, R., Salomaa, V., Sambrook, J., Schreiber, S., Schunkert, H., Schwartz, S.M., Serbanovic-Canic, J., Sinisalo, J., Siscovick, D.S., Stark, K., Surakka, I., Stephens, J., Thompson, J.R., Volker, U., Volzke, H., Watkins, N.A., Wells, G.A., Wichmann, H.E., Van Heel, D.A., Tyler-Smith, C., Thein, S.L., Kathiresan, S., Perola, M., Reilly, M.P., Stewart, A.F., Erdmann, J., Samani, N.J., Meisinger, C., Greinacher, A., Deloukas, P., Ouwehand, W.H., Gieger, C., 2009. A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet 41, 1182–1190.
Stevens, R.G., 2000. Hemochromatosis heterozygotes may constitute a radiation-sensitive subpopulation. Radiat Res 154, 725–726; discussion 726–727.
Stevens, R.G., 2002. Lighting during the day and night: possible impact on risk of breast cancer. Neuro Endocrinol Lett 23(Suppl 2), 57–60.
Stevens, R.G., Kalkwarf, D.R., 1990. Iron, radiation, and cancer. Environ Health Perspect 87, 291–300.
Stevens, R.G., Beasley, R.P., Blumberg, B.S., 1986. Iron-binding proteins and risk of cancer in Taiwan. J Natl Cancer Inst 76, 605–610.
Stevens, R.G., Graubard, B.I., Micozzi, M.S., Neriishi, K., Blumberg, B.S., 1994. Moderate elevation of body iron level and increased risk of cancer occurrence and death. Int J Cancer 56, 364–369.
Stevens, R.G., Jones, D.Y., Micozzi, M.S., Taylor, P.R., 1988. Body iron stores and the risk of cancer. N Engl J Med 319, 1047–1052.
Sullivan, J.L., 2004. Is stored iron safe? J Lab Clin Med 144, 280–284.
Sussman, H.H., 1992. Iron in cancer. Pathobiology 60, 2–9.
Tanaka, T., Roy, C.N., Yao, W., Matteini, A., Semba, R.D., Arking, D., Walston, J.D., Fried, L.P., Singleton, A., Guralnik, J., Abecasis, G.R., Bandinelli, S., Longo, D.L., Ferrucci, L., 2009. A genome-wide association analysis of serum iron concentrations. Blood 115(1), 94–96.
Temme, E.H., Van Hoydonck, P.G., 2002. Tea consumption and iron status. Eur J Clin Nutr 56, 379–386.
The World Cancer Research Fund/American Institute for Cancer Research, 2007. Food, nutrition, physical activity, and the prevention of cancer: a Global Perspective, AICR, Washington, DC.
Thompson, A.B., Bohling, T., Heires, A., Linder, J., Rennard, S.I., 1991. Lower respiratory tract iron burden is increased in association with cigarette smoking. J Lab Clin Med 117, 493–499.
Tiniakos, G., Williams, R., 1988. Cirrhotic process, liver cell carcinoma and extrahepatic malignant tumors in idiopathic haemochromatosis. Study of 71 patients treated with venesection therapy. Appl Pathol 6, 128–138.
Toyokuni, S., 1996. Iron-induced carcinogenesis: the role of redox regulation. Free Radic Biol Med 20, 553–566.
Toyokuni, S., 2002. Iron and carcinogenesis: from Fenton reaction to target genes. Redox Rep 7, 189–197.
Toyokuni, S., 2009. Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer Sci 100, 9–16.
Trowbridge, I.S., Lopez, F., 1982. Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits human tumor cell growth in vitro. Proc Natl Acad Sci U S A 79, 1175–1179.
Trowbridge, I.S., Omary, M.B., 1981. Human cell surface glycoprotein related to cell proliferation is the receptor for transferrin. Proc Natl Acad Sci U S A 78, 3039–3043.
Tuomainen, T.P., Loft, S., Nyyssonen, K., Punnonen, K., Salonen, J.T., Poulsen, H.E., 2007. Body iron is a contributor to oxidative damage of DNA. Free Radic Res 41, 324–328.
Tussing-Humphreys, L.M., Liang, H., Nemeth, E., Freels, S., Braunschweig, C.A., 2009. Excess adiposity, inflammation, and iron-deficiency in female adolescents. J Am Diet Assoc 109, 297–302.
Valko, M., Morris, H., Cronin, M.T., 2005. Metals, toxicity and oxidative stress. Curr Med Chem 12, 1161–1208.
van Asperen, I.A., Feskens, E.J., Bowles, C.H., Kromhout, D., 1995. Body iron stores and mortality due to cancer and ischaemic heart disease: a 17-year follow-up study of elderly men and women. Int J Epidemiol 24, 665–670.
Varkonyi, J., Tarkovacs, G., Karadi, I., Andrikovics, H., Varga, F., Demeter, J., Tordai, A., 2003. High incidence of hemochromatosis gene mutations in the myelodysplastic syndrome: the Budapest Study on 50 patients. Acta Haematol 109, 64–67.
Waladkhani, A.R., Clemens, M.R., 1998. Effect of dietary phytochemicals on cancer development (review). Int J Mol Med 1, 747–753.
Walker, E.M., Jr., Walker, S.M., 2000. Effects of iron overload on the immune system. Ann Clin Lab Sci 30, 354–365.
Ward, P.P., Conneely, O.M., 2004. Lactoferrin: role in iron homeostasis and host defense against microbial infection. Biometals 17, 203–208.
Weinberg, E.D., 1984. Iron withholding: a defense against infection and neoplasia. Physiol Rev 64, 65–102.
Weinberg, E.D., 1996. The role of iron in cancer. Eur J Cancer Prev 5, 19–36.
Weinberg, E.D., 1999. The development of awareness of the carcinogenic hazard of inhaled iron. Oncol Res 11, 109–113.
Weinberg, E.D., 2009. Tobacco smoke iron: an initiator/promoter of multiple diseases. Biometals 22, 207–210.
Weizer-Stern, O., Adamsky, K., Margalit, O., Ashur-Fabian, O., Givol, D., Amariglio, N., Rechavi, G., 2007. Hepcidin, a key regulator of iron metabolism, is transcriptionally activated by p53. Br J Haematol 138, 253–262.
Whitfield, J.B., Cullen, L.M., Jazwinska, E.C., Powell, L.W., Heath, A.C., Zhu, G., Duffy, D.L., Martin, N.G., 2000. Effects of HFE C282Y and H63D polymorphisms and polygenic background on iron stores in a large community sample of twins. Am J Hum Genet 66, 1246–1258.
Whitfield, J.B., Treloar, S., Zhu, G., Powell, L.W., Martin, N.G., 2003. Relative importance of female-specific and non-female-specific effects on variation in iron stores between women. Br J Haematol 120, 860–866.
Wild, P., Bourgkard, E., Paris, C., 2009. Lung cancer and exposure to metals: the epidemiological evidence. Methods Mol Biol 472, 139–167.
Wish, J.B., 2006. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 1(Suppl 1), S4–S8.
Worwood, M., 1997. The laboratory assessment of iron status–an update. Clinica Chimica Acta 259, 3–23.
Wu, K.J., Polack, A., Dalla-Favera, R., 1999. Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-MYC. Science 283, 676–679.
Wu, T., Sempos, C.T., Freudenheim, J.L., Muti, P., Smit, E., 2004a. Serum iron, copper and zinc concentrations and risk of cancer mortality in US adults. Ann Epidemiol 14, 195–201.
Wu, X., Zhao, H., Suk, R., Christiani, D.C., 2004b. Genetic susceptibility to tobacco-related cancer. Oncogene 23, 6500–6523.
Wurzelmann, J.I., Silver, A., Schreinemachers, D.M., Sandler, R.S., Everson, R.B., 1996. Iron intake and the risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 5, 503–507.
Xu, Z., Pan, G.W., Liu, L.M., Brown, L.M., Guan, D.X., Xiu, Q., Sheng, J.H., Stone, B.J., Dosemeci, M., Fraumeni, J.F., Jr., Blot, W.J., 1996. Cancer risks among iron and steel workers in Anshan, China, Part I: Proportional mortality ratio analysis. Am J Ind Med 30, 1–6.
Yu, Y., Kovacevic, Z., Richardson, D.R., 2007. Tuning cell cycle regulation with an iron key. Cell Cycle 6, 1982–1994.
Zacharski, L.R., Chow, B.K., Howes, P.S., Shamayeva, G., Baron, J.A., Dalman, R.L., Malenka, D.J., Ozaki, C.K., Lavori, P.W., 2008. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 100, 996–1002.
Zacharski, L.R., Ornstein, D.L., Woloshin, S., Schwartz, L.M., 2000. Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data. Am Heart J 140, 98–104.
Zafon, C., Lecube, A., Simo, R., 2009. Iron in obesity. An ancient micronutrient for a modern disease. Obes Rev 11(4), 322–328.
Zhang, K.H., Tian, H.Y., Gao, X., Lei, W.W., Hu, Y., Wang, D.M., Pan, X.C., Yu, M.L., Xu, G.J., Zhao, F.K., Song, J.G., 2009. Ferritin heavy chain-mediated iron homeostasis and subsequent increased reactive oxygen species production are essential for epithelial-mesenchymal transition. Cancer Res 69, 5340–5348.
Zheng, H., Cable, R., Spencer, B., Votto, N., Katz, S.D., 2005. Iron stores and vascular function in voluntary blood donors. Arterioscler Thromb Vasc Biol 25, 1577–1583.
Zhou, W., Park, S., Liu, G., Miller, D.P., Wang, L.I., Pothier, L., Wain, J.C., Lynch, T.J., Giovannucci, E., Christiani, D.C., 2005. Dietary iron, zinc, and calcium and the risk of lung cancer. Epidemiology 16, 772–779.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+ Business Media, LLC
About this chapter
Cite this chapter
Davis, C.F., Dorak, M.T. (2010). Iron Excess and Cancer. In: Roy, D., Dorak, M. (eds) Environmental Factors, Genes, and the Development of Human Cancers. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-6752-7_17
Download citation
DOI: https://doi.org/10.1007/978-1-4419-6752-7_17
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-6751-0
Online ISBN: 978-1-4419-6752-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)